Who
Stacy J. Kanter
Director
Company insider
Files Form 4 as: Director, Oppenheimer Holdings; Director, Applied Therapeutics.
In numbers
- Trades disclosed
- 37
- Buys
- 3
- Sells
- 1
- Bought
- $510K
- Sold
- $4,730
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 13 May 2019
- Last trade
- 26 Feb 2026
- Last filed
- 27 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Feb 2026filed 27 Feb 2026 | OPY Oppenheimer HoldingsCapital Markets & Asset Management | SEC FORM 4 Code J | —1,400 | filing |
| 26 Feb 2026filed 27 Feb 2026 | OPY Oppenheimer HoldingsCapital Markets & Asset Management | SEC FORM 4 Code J | —1,400 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code D | —22,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied TherapeuticsBiotechnology | SEC FORM 4 Code U | —42,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —20,460 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —20,460 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —10,230 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code D | —200,000 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —10,230 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —16,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code D | —22,500 | filing |
| 3 Feb 2026filed 4 Feb 2026 | Applied Therapeutics | SEC FORM 4 Code U | —42,500 | filing |
| 16 Dec 2025filed 18 Dec 2025 | Applied Therapeutics | SEC FORM 4 Sold | $4,73043,000 at $0.11 | filing |
| 9 Jun 2025filed 11 Jun 2025 | Applied Therapeuticsoption or derivative | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 30 Jan 2025filed 31 Jan 2025 | OPY Oppenheimer HoldingsCapital Markets & Asset Management | SEC FORM 4 Code J | —1,500 | filing |
| 6 Jun 2024filed 7 Jun 2024 | Applied Therapeutics | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.